^
    2ms
    WU-CART-007 1001: A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov)
    P1, N=28, Completed, Wugen, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    WU CART 007
    5ms
    WUC007-03: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=125, Recruiting, Wugen, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    WU CART 007
    6ms
    Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies. (PubMed, Blood)
    WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
    P1/2 data • Journal
    |
    CD7 (CD7 Molecule)
    |
    WU CART 007
    7ms
    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=54 --> 6
    Enrollment closed • Enrollment change
    |
    CD7 (CD7 Molecule)
    |
    WU CART 007
    8ms
    WUC007-03: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Wugen, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    WU CART 007
    10ms
    WUC007-03: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=125, Recruiting, Wugen, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    WU CART 007
    12ms
    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
    P1, N=54, Recruiting, Washington University School of Medicine | Active, not recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 expression
    |
    WU CART 007
    1year
    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=54 --> 6
    Enrollment closed • Enrollment change • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 expression
    |
    WU CART 007
    over1year
    Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. (PubMed, Res Sq)
    WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
    P1/2 data • Journal
    |
    CD7 (CD7 Molecule)
    |
    WU CART 007
    over1year
    WU-CART-007 1001: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov)
    P1/2, N=29, Completed, Wugen, Inc. | Active, not recruiting --> Completed | N=44 --> 29 | Trial completion date: Aug 2026 --> Jun 2024 | Trial primary completion date: May 2026 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    WU CART 007
    over1year
    A Phase 2 Study WU-CART-007 in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=125, Not yet recruiting, Wugen, Inc.
    New P2 trial • CAR T-Cell Therapy • Minimal residual disease
    |
    WU CART 007
    almost2years
    A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov)
    P1/2, N=44, Active, not recruiting, Wugen, Inc.
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    WU CART 007